直肠癌新辅助治疗疗效评价体系的现状与思考  

Current situation and thinking of efficacy evaluation system for the neoadjuvant therapy of rectal cancer

作　　者：张宇 方媛[1] 刘伟臻 张夏青 朱勇[1] ZHANG Yu;FANG Yuan;LIU Weizhen;ZHANG Xiaqing;ZHU Yong(Department of Proctology,Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210022,China)

机构地区：[1]南京中医药大学附属南京中医院肛肠科,江苏南京210000

出　　处：《中国肿瘤外科杂志》2022年第5期509-514,共6页Chinese Journal of Surgical Oncology

基　　金：南京市医学科技发展项目(YKK17151)。

摘　　要：近年来直肠癌在我国的发病率和病死率保持上升的趋势,多数患者发现时已属于中晚期,极大程度影响着患者的预后。中低位直肠癌患者接受新辅助治疗后肿瘤会有一定程度退缩,甚至消失。对于外科医生而言,如何精准评估新辅助治疗后的疗效,直接决定着患者后续治疗方案的制定。该文旨在对直肠癌新辅助治疗后的临床疗效评价体系做一系统综述,希望能够通过现有的技术手段帮助外科医生提升临床疗效评估的准确性,为后续治疗策略的选择提供帮助。In recent years,the incidence and mortality of rectal cancer in China have maintained an upward trend.Most of the patients have been found to be in the middle and advanced stage,which greatly affects the prognosis of patients.The tumor in the patients with middle and low rectal cancer will retreat or even disappear to a certain extent after neoadjuvant therapy.For surgeons,accurate assessment on the efficacy of neoadjuvant therapy directly determines the formulation of patients follow-up treatment plan.The purpose of this paper is to make a systematic review on the clinical efficacy evaluation system after neoadjuvant therapy for rectal cancer,and to improve the accuracy of clinical efficacy evaluation through the existing technical means and provide help for the choice of follow-up treatment strategies.

关 键 词：直肠癌 新辅助化学疗法 临床完全缓解 临床疗效评价 

分 类 号：R735.37[医药卫生—肿瘤]